{
    "organizations": [],
    "uuid": "44c1bc33ca8b7986502ab38d41582195ab144306",
    "author": "",
    "url": "https://www.reuters.com/article/brief-gilead-sciences-says-fda-approves/brief-gilead-sciences-says-fda-approves-biktarvy-for-treatment-of-hiv-1-infection-idUSASM000J22",
    "ord_in_thread": 0,
    "title": "BRIEF-Gilead Sciences Says FDA Approves Biktarvy For Treatment Of HIV-1 Infection",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "February 7, 2018 / 7:28 PM / in 15 minutes BRIEF-Gilead Sciences Says FDA Approves Biktarvy For Treatment Of HIV-1 Infection Reuters Staff 1 Min Read \nFeb 7 (Reuters) - Gilead Sciences Inc: \n* U.S. FOOD AND DRUG ADMINISTRATION APPROVES GILEAD’S BIKTARVY® (BICTEGRAVIR, EMTRICITABINE, TENOFOVIR ALAFENAMIDE) FOR TREATMENT OF HIV-1 INFECTION \n* GILEAD SCIENCES INC - BIKTARVY HAS A BOXED WARNING IN ITS PRODUCT LABEL REGARDING RISK OF POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B \n* GILEAD SCIENCES - ‍ADDITIONAL CLINICAL TRIALS OF BIKTARVY ONGOING, INCLUDING A DEDICATED STUDY IN WOMEN; PLANS TO PRESENT DATA FROM STUDIES IN 2018​ \n* GILEAD SCIENCES - APPROVAL OF BIKTARVY SUPPORTED BY DATA FROM 4 ONGOING PHASE 3 STUDIES INCLUDING STUDIES 1489 & 1490 IN TREATMENT-NAÏVE HIV-1 INFECTED ADULTS \n* GILEAD SCIENCES - APPROVAL OF BIKTARVY SUPPORTED BY DATA FROM 4 ONGOING PHASE 3 STUDIES INCLUDING STUDIES 1844 & 1878 IN VIROLOGICALLY SUPPRESSED ADULTS Source text for Eikon: Further company coverage:",
    "published": "2018-02-07T21:27:00.000+02:00",
    "crawled": "2018-02-07T21:55:17.003+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "february",
        "pm",
        "minute",
        "science",
        "say",
        "fda",
        "approves",
        "biktarvy",
        "treatment",
        "infection",
        "reuters",
        "staff",
        "min",
        "read",
        "feb",
        "reuters",
        "gilead",
        "science",
        "inc",
        "food",
        "drug",
        "administration",
        "approves",
        "gilead",
        "bictegravir",
        "emtricitabine",
        "tenofovir",
        "alafenamide",
        "treatment",
        "infection",
        "gilead",
        "science",
        "inc",
        "biktarvy",
        "boxed",
        "warning",
        "product",
        "label",
        "regarding",
        "risk",
        "post",
        "treatment",
        "acute",
        "exacerbation",
        "hepatitis",
        "b",
        "gilead",
        "science",
        "clinical",
        "trial",
        "biktarvy",
        "ongoing",
        "including",
        "dedicated",
        "study",
        "woman",
        "plan",
        "present",
        "data",
        "study",
        "gilead",
        "science",
        "approval",
        "biktarvy",
        "supported",
        "data",
        "ongoing",
        "phase",
        "study",
        "including",
        "study",
        "infected",
        "adult",
        "gilead",
        "science",
        "approval",
        "biktarvy",
        "supported",
        "data",
        "ongoing",
        "phase",
        "study",
        "including",
        "study",
        "virologically",
        "suppressed",
        "adult",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}